Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Below 200 Day Moving Average – Time to Sell?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $28.05 and traded as low as $20.17. Capricor Therapeutics shares last traded at $20.61, with a volume of 1,273,818 shares traded.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CAPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Roth Capital reiterated a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

Capricor Therapeutics Stock Down 1.6%

The company has a market cap of $1.18 billion, a price-to-earnings ratio of -8.77 and a beta of 0.42. The business has a fifty day simple moving average of $27.17 and a 200 day simple moving average of $27.99.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Equities analysts anticipate that Capricor Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,000 shares of company stock worth $1,551,658 in the last quarter. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the 1st quarter worth approximately $44,000. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics during the fourth quarter worth $43,000. GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics during the fourth quarter worth $59,000. Allworth Financial LP grew its holdings in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares during the last quarter. Finally, State of Wyoming grew its holdings in Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.